PainReform Ltd. (PRFX)
USD 2.07
(-0.48%)
USD 2.07
(-0.48%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.69 Million USD | 105.89% |
| 2022 | 1.3 Million USD | 31.89% |
| 2021 | 991 Thousand USD | -16.09% |
| 2020 | 1.18 Million USD | -82.6% |
| 2019 | 6.78 Million USD | 49.54% |
| 2018 | 4.53 Million USD | 18.08% |
| 2017 | 3.84 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 5.14 Million USD | 46.21% |
| 2024 Q1 | 3.52 Million USD | 30.84% |
| 2023 Q4 | 2.69 Million USD | 19.81% |
| 2023 FY | 2.69 Million USD | 105.89% |
| 2023 Q3 | 2.24 Million USD | 67.24% |
| 2023 Q2 | 1.34 Million USD | -11.99% |
| 2023 Q1 | 1.52 Million USD | 16.76% |
| 2022 Q1 | 1 Million USD | 1.31% |
| 2022 FY | 1.3 Million USD | 31.89% |
| 2022 Q4 | 1.3 Million USD | -8.86% |
| 2022 Q3 | 1.43 Million USD | 82.21% |
| 2022 Q2 | 787 Thousand USD | -21.61% |
| 2021 FY | 991 Thousand USD | -16.09% |
| 2021 Q1 | 954 Thousand USD | -19.22% |
| 2021 Q3 | 856 Thousand USD | 2.76% |
| 2021 Q4 | 991 Thousand USD | 15.77% |
| 2021 Q2 | 833 Thousand USD | -12.68% |
| 2020 FY | 1.18 Million USD | -82.6% |
| 2020 Q4 | 1.18 Million USD | 0.0% |
| 2020 Q2 | 8.38 Million USD | 0.0% |
| 2020 Q1 | - USD | -100.0% |
| 2019 Q3 | 6.33 Million USD | 27.44% |
| 2019 Q2 | 4.97 Million USD | 0.0% |
| 2019 Q1 | 4.97 Million USD | 9.61% |
| 2019 Q4 | 6.78 Million USD | 7.05% |
| 2019 FY | 6.78 Million USD | 49.54% |
| 2018 Q3 | 4.53 Million USD | 0.0% |
| 2018 Q4 | 4.53 Million USD | 0.0% |
| 2018 FY | 4.53 Million USD | 18.08% |
| 2018 Q1 | - USD | 0.0% |
| 2017 FY | 3.84 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 99.716% |
| Embecta Corp. | 2.03 Billion USD | 99.868% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 99.429% |
| Dynavax Technologies Corporation | 375.02 Million USD | 99.282% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 99.593% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 99.618% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 98.358% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | 56.17% |
| SCYNEXIS, Inc. | 55.45 Million USD | 95.147% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | 70.739% |
| Cosmos Health Inc. | 30.25 Million USD | 91.105% |
| Journey Medical Corporation | 56.49 Million USD | 95.237% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | 56.17% |
| Safety Shot Inc | 3.89 Million USD | 30.859% |
| Alpha Teknova, Inc. | 38.55 Million USD | 93.02% |
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 98.034% |
| Bright Green Corporation | 6.43 Million USD | 58.202% |
| Procaps Group, S.A. | 462.06 Million USD | 99.418% |
| Theratechnologies Inc. | 98.63 Million USD | 97.272% |
| Harrow Health, Inc. | 241.75 Million USD | 98.887% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | 69.267% |
| Biofrontera Inc. | 23.13 Million USD | 88.37% |
| DURECT Corporation | 30.4 Million USD | 91.15% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 99.448% |
| Cronos Group Inc. | 43.73 Million USD | 93.847% |
| OptiNose, Inc. | 194.33 Million USD | 98.615% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 99.671% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 94.445% |
| RedHill Biopharma Ltd. | 20.97 Million USD | 87.172% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 98.516% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | 28.661% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 94.876% |
| Radius Health, Inc. | 804.29 Million USD | 99.665% |
| Universe Pharmaceuticals INC | 13.75 Million USD | 80.435% |
| ProPhase Labs, Inc. | 42.54 Million USD | 93.675% |
| Phibro Animal Health Corporation | 725.54 Million USD | 99.629% |
| Procaps Group S.A. | 462.06 Million USD | 99.418% |
| Alvotech | 1.88 Billion USD | 99.857% |
| TherapeuticsMD, Inc. | 14.02 Million USD | 80.809% |
| Viatris Inc. | 27.21 Billion USD | 99.99% |
| Rockwell Medical, Inc. | 30.88 Million USD | 91.286% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 97.023% |
| SIGA Technologies, Inc. | 57.97 Million USD | 95.359% |
| Tilray Brands, Inc. | 892.11 Million USD | 99.698% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 98.776% |
| Shineco, Inc. | 47.6 Million USD | 94.347% |
| PetIQ, Inc. | 645.22 Million USD | 99.583% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -1125.901% |
| Incannex Healthcare Limited | 5.83 Million USD | 53.842% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 99.736% |
| Alimera Sciences, Inc. | 107.35 Million USD | 97.493% |
| Silver Spike Investment Corp. | 3 Million USD | 10.593% |
| Assertio Holdings, Inc. | 148.41 Million USD | 98.187% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -41.933% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | 87.376% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | 61.699% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 68.306% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 98.448% |
| Hempacco Co., Inc. | 18.82 Million USD | 85.703% |
| Talphera, Inc. | 6.29 Million USD | 57.218% |
| Alvotech | 1.88 Billion USD | 99.857% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 98.441% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 99.678% |
| Currenc Group, Inc. | 177.67 Million USD | 98.485% |
| Kamada Ltd. | 109.96 Million USD | 97.553% |
| Indivior PLC | 1.95 Billion USD | 99.862% |
| Evoke Pharma, Inc. | 9.64 Million USD | 72.108% |
| Flora Growth Corp. | 17.22 Million USD | 84.375% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | 68.306% |
| Evolus, Inc. | 209.68 Million USD | 98.717% |
| HUTCHMED (China) Limited | 536.38 Million USD | 99.498% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 99.692% |
| Akanda Corp. | 12.66 Million USD | 78.759% |